Torasemide Hexal

Quick links to important sections

Torasemide Hexal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Torasemide Hexal

Quick Facts

Property Description
Active ingredient Torasemide (INN)
Form Oral film-coated tablet
Pharmacological class Loop Diuretic
Common use Reducing fluid retention (edema)
Origin Synthetic compound
RX Status Prescription-only (Rx)

What Type of Drug is Torasemide Hexal?

Torasemide Hexal is a specific brand of a loop diuretic, which is a prescription-only (Rx) medication used to reduce fluid accumulation in the body. Its sole active ingredient is torasemide (INN), a synthetic compound manufactured by Hexal AG. The active substance, torasemide, is clinically recognized for its high and stable bioavailability, ensuring predictable absorption after oral intake. Unlike some older diuretics, torasemide is classified as a high-ceiling diuretic, meaning it is designed for a potent effect on the kidneys.

What is the Composition and Form?

The composition of Torasemide Hexal contains the active substance torasemide, delivered as an oral film-coated tablet. The medication is intended for oral administration, and its formulation helps ensure ease of swallowing. While “Hexal” identifies the distributor, the core therapeutic function is maintained by the torasemide molecule. This specific compound has a more prolonged effect compared to some conventional alternatives, sustaining the action of removing excess fluid over a longer period.

What is the General Therapeutic Goal of Torasemide?

The fundamental therapeutic goal of torasemide is to correct volume overload by strongly increasing the excretion of water and sodium by the kidneys. This action promotes the loss of excess fluid, thereby alleviating the symptoms of edema, or swelling. Loop diuretics like torasemide are a standard intervention for reducing edema in cases of heart failure and managing fluid retention associated with serious kidney or liver conditions.

What side effects are possible with Torasemide Hexal?

Torasemide Hexal, as a loop diuretic, has a documented safety profile established in official regulatory documents that outlines the systemic effects and classified frequencies of adverse reactions observed in clinical practice.

Official Systemic Classification of Adverse Reactions

The most frequent adverse effects are generally linked to the medication's core function of regulating fluid and electrolyte balance. Adverse effects are organized by frequency and the physiological systems they involve.

Common Effects

Reactions classified as Common (affecting up to 1 in 10 patients) typically involve Metabolism and nutrition disorders, such as fluid and electrolyte imbalance (e.g., hypovolaemia, hyponatraemia) and metabolic alkalosis. Effects on the Nervous system commonly include headache and dizziness, while Gastrointestinal disorders may manifest as nausea, vomiting, or changes in bowel habits. Fatigue and muscle spasms are also listed in this category.

Uncommon and Serious Reactions

Uncommon effects (affecting up to 1 in 100 patients) include increases in various laboratory markers, such as hepatic enzymes, blood glucose, uric acid, and lipids. The official profile documents serious adverse reactions, often of frequency not known, which span multiple systems. These include cardiac and vascular disorders such as acute myocardial infarction, embolism, and hypotension. Serious safety events also include the rare possibility of hepatic coma in patients with pre-existing hepatic disease, and rare serious skin reactions such as Stevens-Johnson syndrome.

Safety Considerations in Specific Populations

Official labeling defines specific constraints for certain patient groups. Torasemide is contraindicated in hepatic coma and pre-coma and during pregnancy and lactation. Caution is specifically noted for older adults due to an elevated risk of thrombosis and embolism resulting from excessive volume reduction. Furthermore, patients with pre-existing urinary flow disorders must be monitored due to the potential for acute urinary retention.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for torasemide overdose is defined by the severe consequences of its exaggerated pharmacological effect: marked diuresis and subsequent excessive fluid and electrolyte loss.

Overdose manifestations primarily affect fluid balance and the central nervous system (CNS):

System/Condition Documented Manifestation
CNS Effects Somnolence, confusional state
Cardiovascular Hypotension, risk of circulatory collapse
Metabolic Hyponatremia, hypokalemia, hypochloremic alkalosis

Required Emergency Actions

Immediate medical attention is required in the event of a suspected or confirmed overdose, particularly if symptoms of severe dehydration or hypotension are present. Regulatory documents list the most serious complications as circulatory collapse and the potential for thrombosis due to severe hemoconcentration.

No specific antidote is known for torasemide overdose. Therefore, the official management is symptomatic and supportive, mandated to include the simultaneous replacement of fluid and electrolytes lost due to the potent diuretic action. Close monitoring of kidney function and serum electrolytes is essential during this supportive care. Excessive fluid loss carries a specific risk of thrombosis and embolism, especially in elderly patients, as documented in official labeling.

Therapeutic Uses of Torasemide Hexal

What Torasemide Hexal Treats: Main Uses and Benefits

The active ingredient in Torasemide Hexal is torasemide, which is commonly used for the management of fluid retention across several major disease categories. This medication is applied in addressing symptoms related to systemic imbalance in conditions characterized by periods of heightened symptoms.

The primary therapeutic domains include chronic heart failure, where it helps address symptoms related to physical discomfort; edematous syndromes resulting from liver cirrhosis; and fluid accumulation associated with chronic kidney disease. It is also relevant for managing certain cases of hypertension (high blood pressure) where volume regulation is needed as part of a combination regimen. The medication supports the reduction of pronounced fluid accumulation, such as peripheral edema in the limbs and ascites (abdominal fluid buildup).

“Torasemide helps address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.”

In contexts involving heightened systemic burden, Torasemide Hexal assists with maintaining functional stability and contributes to easing the overall symptom load associated with chronic volume overload, which supports general well-being during symptomatic phases.


Quick Fact: Relief for Swelling and Breathlessness

Property Description
Main Condition Treated Fluid Overload (Edema)
Core Symptom Relief Swelling (peripheral/abdominal) and Shortness of Breath
Therapeutic Goal Supporting fluid regulation and easing symptom burden
Clinical Context Long-term symptomatic support in chronic heart, liver, and kidney disease

Regulatory References

  1. Torsemide (Torasemide) Drug Label

Eligibility and Restrictions for Use

Torasemide Hexal eligibility is determined by strict criteria defined in official regulatory documents. Use of the medicine is generally approved for adults managing fluid retention associated with chronic heart failure, chronic renal disease, or hepatic cirrhosis. It is also used to manage hypertension.

Eligibility Status Key Restriction/Prohibition
Contraindicated Anuria (inability to pass urine), Hepatic Coma, known Hypersensitivity to torasemide or sulfonylureas.
Restricted Use Existing Hypovolemia, Hypotension, and uncorrected Electrolyte Imbalances (e.g., low potassium).

The medicine's safety and efficacy are not established for use in the pediatric population (children under 12 years of age). For older adults, no specific age-related limitations exist, though caution is noted due to the higher prevalence of organ impairment.

Regarding reproductive status, use during pregnancy is not generally recommended unless the clinical necessity outweighs potential risks. Torasemide is often contraindicated during lactation by some authorities due to the unknown risk to the nursing infant. Treatment for severe hepatic disease should be initiated with caution, ideally in a controlled setting.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Torasemide Hexal's interaction profile is defined by officially documented effects on drug exposure and additive pharmacodynamic risks, as specified in regulatory labeling.


Documented Pharmacokinetic Alterations

Substance Category Documented Outcome
CYP2C9 Inhibitors (e.g., Fluconazole) Increase torasemide plasma concentrations and decrease torasemide clearance.
CYP2C9 Inducers (e.g., Rifampin) Decrease torasemide plasma concentrations and increase torasemide clearance.
Digoxin Co-administration is reported to increase the Area Under the Curve (AUC) for torasemide.
Cholestyramine Decreased absorption of orally administered torasemide.

Documented Pharmacodynamic Interactions

Torasemide may potentiate the effects or toxicity of the following substances:

  • Antihypertensive Agents (e.g., ACE Inhibitors): Potentiation of the hypotensive effect, increasing the risk of severe hypotension and renal impairment.
  • Ototoxic / Nephrotoxic Drugs (e.g., Aminoglycoside Antibiotics, Cisplatin): Potentiation of ototoxic and nephrotoxic effects.
  • Lithium: May increase serum lithium concentrations, raising the risk of cardiotoxic and neurotoxic effects.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): May reduce the diuretic effect of torasemide and increase the risk of acute renal failure.
  • Corticosteroids / Laxatives: Enhanced kaliuresis, increasing the risk of hypokalemia.

Mandatory Administration Timing

Due to reduced absorption, torasemide must be administered at least one hour before or 4 to 6 hours after the administration of Cholestyramine.

Population-Specific Notes

In patients with hepatic impairment, torasemide plasma concentrations might be increased. Excessive diuresis enhances the risk of hepatic coma in this population.

Mechanism of Action

Primary Mechanism: Inhibition of the Kidney's NKCC2 Cotransporter

Torasemide Hexal's primary action involves the direct competitive blockade of the Sodium-Potassium-Chloride Cotransporter 2 ( NKCC2), a transport protein located on the cells of the kidney's Thick Ascending Loop of Henle ( TALH). By inhibiting this transporter, the drug prevents the reabsorption of a substantial fraction of filtered sodium ( Na^+), chloride ( Cl^-), and potassium ( K^+) from the tubular fluid back into the bloodstream. This molecular interaction modifies the kidney's electrolyte reabsorption dynamics.


Causal Cascade and Systemic Volume Modulation

The resulting increase in unreabsorbed salt concentration within the kidney tubule creates an osmotic gradient. This osmotic pressure retains water, forcing it to be excreted along with the electrolytes, resulting in natriuresis (sodium excretion) and diuresis (water excretion). This cascade of events systemically drives the reduction of total Extracellular Fluid ( ECF) volume, which decreases the volume of blood returning to the heart (preload).


Secondary Hormonal and Tissue Influence

Torasemide demonstrates a secondary, dose-dependent influence on the Renin-Angiotensin-Aldosterone System ( RAAS), specifically by modulating the effect of aldosterone. This secondary modulation of hormonal volume control results in a reduced rate of potassium excretion compared to drugs lacking this influence, which contributes to the overall effect on systemic electrolyte handling. Additionally, this action is associated with a mechanism that modulates pathways governing the deposition of collagen and tissue fibrosis in specific organ systems.

Dosage and Administration Information

Torasemide Hexal is used in an oral regimen, administered as a film-coated tablet which must be swallowed whole with fluid, regardless of food intake. The frequency for all approved indications is once daily. Official instructions recommend taking the dose in the morning to align with the active period of the medicine.


Official Dosing Regimens

Dosing is determined by the condition being managed. For edema (fluid retention), the initial dose is typically 10 mg or 20 mg once daily. The dose can be sequentially doubled as needed to achieve the desired effect, up to a maximum labeled dose of 200 mg daily. Conversely, for the management of hypertension, the initial labeled dose is lower at 5 mg once daily, with a maximum labeled dose of 10 mg per day.


Procedural and Population Rules

Torasemide Hexal is typically part of a long-term plan. No special dose adjustment is required for older adults according to regulatory labels. Safety and efficacy for pediatric use have not been established. In the event of a missed daily dose, the official instruction is to skip the missed dose if it is almost time for the next scheduled dose, and never to take a double dose to compensate. For edema linked to hepatic cirrhosis, torasemide administration must be combined with a potassium-sparing diuretic.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trial Analysis

Studies investigated the effects of this compound in participants diagnosed with condition X. These Phase 3 trials evaluated the compound in a large group of participants across multiple sites.

  • Fluid Retention: Research examined whether the compound was associated with changes in measures of excess fluid.
  • Cardiac Function: Studies assessed indicators of cardiac stress in participants receiving the compound over time. This analysis involved measuring specific biological indicators throughout the trial period.

Subgroup and Combination Research

Combination Therapy

Research investigated changes in fluid volume in participants receiving the combination regimen. Safety data was collected during the trials.

  • The research specifically focused on the administration of the compound alongside existing standard-of-care treatments for a defined period. Evidence regarding the studied duration or different combinations remains limited.

Specific Patient Populations

Studies of patients with existing renal impairment were reviewed to evaluate the compound in this population. The data collected was intended to inform researchers about potential differences in the compound’s evaluation compared to the general study population.


Summary of Trial Data

Key Findings Context

The data reviewed describes the observations recorded during the clinical research studies. The research evaluated the compound's effect on various markers of cardiac and renal function, as well as on systemic fluid balance. This summary does not provide medical advice, diagnosis, or treatment recommendations. The information gathered does not imply a predictable outcome for any individual.

Key Studies & References Public Assessment Report Scientific discussion Torasemid Zentiva (torasemide (anhydrous)) SE/H/2278/01-04/DC (European Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Torasemide Hexal (FAQ)


Q: What happens if I forget to take a dose of Torasemide Hexal?

If you remember that you missed a dose and it is almost time for your next scheduled dose, official instructions state to skip the missed dose completely. Official instructions advise against taking a double dose to compensate for a missed one. If there is uncertainty about a missed dose, consultation with a healthcare professional for guidance is described in the official instructions.


Q: How quickly does Torasemide Hexal usually start working after taking it?

According to the official prescribing information, the onset of diuresis, which is the process of increased urination, typically begins within one hour after taking the oral tablet. The peak effect is typically reported to occur during the first or second hour, and the overall effect usually lasts for about six to eight hours.


Q: Is it common to need to use the toilet more frequently when taking this medicine?

Yes, excessive urination (known medically as polyuria) is the most common adverse reaction reported in official safety labeling. This effect is expected as it is the core action of the medication, which works by increasing the excretion of water and salt from the kidneys.


Q: Can Torasemide Hexal cause dehydration, and what are the signs?

As a potent diuretic, Torasemide Hexal can lead to excessive loss of body fluid, which may result in dehydration or hypovolemia (low blood volume). Official warnings describe signs of fluid loss that may warrant consultation with a healthcare professional, such as dry mouth, unusual thirst, weakness, dizziness, or muscle cramps.


Q: Are there any known issues with taking Torasemide Hexal and alcohol?

Official information indicates that alcohol and Torasemide Hexal may have additive effects in lowering blood pressure. This combination is associated with an increased risk of symptoms related to low blood pressure, such as dizziness or lightheadedness.


Q: Can Torasemide Hexal cause changes to blood sugar levels?

Official product information notes that treatment with torasemide has the potential to cause an increase in blood glucose levels, leading to a condition called hyperglycemia. Official guidance indicates that serum electrolytes and blood glucose are typically monitored periodically during this treatment.


Q: Does taking Torasemide Hexal affect my potassium levels?

The use of this medication can cause changes to the body's balance of electrolytes and minerals. These potential changes include hypokalemia (low potassium levels), hypomagnesemia (low magnesium levels), and hypocalcemia (low calcium levels). The label indicates that monitoring of these levels is typically conducted.


Q: Why are people sometimes switched from another diuretic to Torasemide?

Regulatory-cited literature describes Torasemide as having a more prolonged duration of action compared to some conventional alternatives. This characteristic supports its common use in a once-daily dosing regimen.


Q: Is it normal to feel a little dizzy when first starting Torasemide Hexal?

Dizziness and headache are listed in official safety profiles as common effects that may be experienced. These symptoms are listed as common effects that may be experienced, particularly at the start of treatment or following a dose change.


Q: Is there any research on Torasemide for liver-related fluid retention?

Yes, Torasemide is officially indicated for the treatment of edema (fluid retention) associated with hepatic disease, such as hepatic cirrhosis. This indication is supported by evidence derived from specific clinical investigations.


Q: How does Torasemide Hexal differ from other loop diuretics in terms of how long it lasts?

Official regulatory documents indicate that the oral form of torasemide has a duration of diuretic action lasting approximately six to eight hours. This is noted as being a longer duration of effect compared to some common alternatives in the loop diuretic class.


Q: Can Torasemide Hexal affect hearing or cause tinnitus?

Official warnings note the potential for ototoxicity, which means a risk of damage to the ear. Patients are advised that they should report any symptoms related to hearing loss or a ringing, buzzing, or roaring sound in the ears (tinnitus).


Q: Does Torasemide Hexal have the potential to interact with herbal supplements?

While specific herbal products are not uniformly listed in all drug labels, official guidance consistently advises patients to inform their healthcare team about all products they use. This includes all herbs, non-prescription drugs, and dietary supplements, due to the potential for interaction risks.


Q: Is it generally safe for people who drive or operate machinery to take this medicine?

Because adverse effects such as dizziness can occur, especially when treatment is first initiated, the ability to safely drive or operate heavy machinery may be impaired. Official guidance advises caution in performing these activities.


Q: Is it safe to use Torasemide Hexal if I have diabetes?

Official warnings note that Torasemide Hexal may cause an increase in blood glucose levels. Official warnings for patients with diabetes indicate that blood glucose levels are typically monitored periodically during treatment.


Q: Are there general dietary suggestions for people taking a diuretic like Torasemide?

The action of the medication depends on achieving a balance between the sodium lost by the kidneys and the amount of sodium consumed in the diet. Official guidance indicates that limiting dietary sodium intake is typically considered part of the overall management plan.


Q: Is Torasemide Hexal the same type of medicine as Furosemide?

Torasemide, the active ingredient in Torasemide Hexal, is classified as a loop diuretic, which places it in the same drug class as Furosemide. However, Torasemide has a different chemical structure and is noted to have a longer duration of action in the body.


Q: What kind of side effects are most often reported with Torasemide Hexal?

The most commonly reported side effect in clinical trials and listed on the official label is excessive urination (polyuria). Other common effects documented in the safety profile include headache, dizziness, and gastrointestinal issues such as nausea.


Q: Are there any specific foods or drinks I should limit while on Torasemide Hexal?

Due to the potential for excessive fluid and electrolyte loss, the medication is generally managed alongside a controlled or limited sodium diet. Alcohol consumption is also noted in official information to potentially increase the blood pressure lowering effect.


Q: What does 'Torasemide' mean, and what is the 'Hexal' part?

Torasemide is the name of the active chemical ingredient in the medicine, classified as a loop diuretic. Hexal refers to the name of the manufacturer or distributor that produces this specific brand-name product.


Q: Is there a generic version of Torasemide Hexal?

Yes, the active ingredient in this medication, torasemide, is widely available as a generic status drug. The brand name, Torasemide Hexal, is one of the available products containing this active ingredient.


Q: What should I do if a side effect seems mild but doesn't go away?

For adverse effects such as mild dizziness or headache that persist, official patient information suggests consulting with a healthcare professional or pharmacist promptly. They can determine if the symptom is manageable or if it requires a change in management.


Q: Does this medicine have a known 'rebound effect' if stopped suddenly?

Official prescribing information concerning the drug's use for essential hypertension indicates that when administration is stopped suddenly, blood pressure typically returns to pre-treatment levels over several days, but without an overshoot or 'rebound effect'.


Q: Can Torasemide Hexal interact with over-the-counter pain relievers?

Regulatory documentation states that Torasemide Hexal interacts with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are found in some over-the-counter pain relievers. This combination may reduce the diuretic effect and increase the risk of potential renal impairment.


Q: Does Torasemide Hexal affect cholesterol levels?

Official safety profiles list an uncommon adverse effect involving an increase in lipids. Lipids is the physiological category that includes cholesterol, suggesting a potential effect on these levels.


Q: Is it true that this drug can cause magnesium levels to drop?

Yes, official warnings confirm that Torasemide can cause imbalances in electrolytes, including hypomagnesemia (low magnesium levels). The label advises that magnesium and other serum electrolytes should be monitored.


Q: Are there documented cases of allergic reactions to Torasemide Hexal?

Official documents state that the medicine is contraindicated in patients with known hypersensitivity to the active ingredient, torasemide, or to sulfonylureas. Hypersensitivity indicates a risk of allergic reaction.


Q: What does official guidance say about the risk of gout while on Torasemide?

The official label notes that torasemide can cause an increase in uric acid levels in the blood. Because of this, the official guidance advises caution and monitoring for patients with a medical history of gout.


Q: How does the onset of action of Torasemide compare to other common diuretics?

Official documentation indicates that the onset of increased urine output typically begins within one hour of administration. The duration of the effect, lasting about six to eight hours, is noted as being longer compared to some other common loop diuretics.


Q: Is Torasemide Hexal known to cause muscle cramps or weakness?

Official safety documents list muscle spasms as a common adverse effect. Symptoms related to electrolyte imbalance, such as muscle pains, cramps, or muscular fatigue, are also documented.


Q: Can Torasemide Hexal interact with antacids or heartburn medicines?

Torasemide is documented to interact with Cholestyramine, which can significantly reduce the absorption of torasemide. Some antacid components may also interact due to the risk of increased fluid loss.


Q: Are there specific clinical trials that define the use of Torasemide in heart failure?

Yes, the use and effects of torasemide in managing fluid retention associated with heart failure have been and continue to be the subject of specific clinical research. These trials are often registered in and evaluated by official government databases.


Q: Does Torasemide Hexal commonly cause stomach upset or nausea?

Gastrointestinal disorders are listed as common adverse effects in official safety profiles. These problems may be experienced as nausea, vomiting, or changes in bowel habits.

How should Torasemide Hexal be stored and disposed of?

How to Store and Dispose of Torasemide Hexal

Official regulatory documents define specific requirements for storing and disposing of Torasemide Hexal tablets to maintain product quality and safety.


Storage and Handling

Torasemide Hexal must be stored properly to protect its stability. The medicine must not be stored above 30 C and must be kept away from excessive heat and freezing. To protect the product from moisture, it is required to store it in the original package and keep the bottle tightly closed.

Storage Classification Requirement
Temperature Do not store above 30 C
Protection Keep in original package; protect from moisture

All medicine must be kept out of the reach of children.


Disposal Instructions

Do not keep outdated medicine or medicine that is no longer needed. Official disposal guidance instructs users to ask a healthcare professional or pharmacist how to safely dispose of any unused medicine. It is typically recommended to utilize a local pharmacy or community drug take-back program for proper disposal, ensuring the medicine does not enter drains or the general waste stream.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Torasemide Hexal found in:

A-Z Index: